FDA notified healthcare professionals that it is aware of the study published in the New England Journal of Medicine reporting a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. FDA is reviewing the results from this study and will communicate any new information on azithromycin and this study or the potential risk of QT interval prolongation after the agency has completed its review.
The New England Journal of Medicine study was based on an examination of patient records from 1992 to 2006. A second study was done by the researchers at Vanderbilt University and compared about 348,000 prescriptions of azithromycin to millions of records from people who were not treated with any antibiotics or who received amoxicillin.
Poulos LoPiccolo is investigating claims against the manufacturer and the connection between Zithromax and its risk of serious heart risks that may boost the risk of death compared to another or no antibiotic.
If you or your loved one suffered a cardiac event while ingesting Zithromax, please call us toll free at 800-757-2304 or email us at firstname.lastname@example.org one of our attorneys will immediatly get back to you.